azacitidine and Albuminuria

azacitidine has been researched along with Albuminuria in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, Y; Huang, Z; Li, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Shi, W; Tan, X; Wang, W; Ye, Z; Yu, C; Zhang, B; Zhang, H; Zhang, L; Zhang, Q; Zhao, X	1

Other Studies

1 other study(ies) available for azacitidine and Albuminuria

Article	Year
DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney international, 2017, Volume: 92, Issue:1 Topics: Albuminuria; Animals; Azacitidine; Binding Sites; Cell Line; Cell Movement; Cell Proliferation; Cytoprotection; Decitabine; Diabetes Mellitus; Diabetic Nephropathies; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Male; Mice, Inbred C57BL; Podocytes; Promoter Regions, Genetic; RNA Interference; Sp1 Transcription Factor; Time Factors; Transcription Factor RelA; Transfection	2017

Article

Year

DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury.

Kidney international, 2017, Volume: 92, Issue:1

Topics: Albuminuria; Animals; Azacitidine; Binding Sites; Cell Line; Cell Movement; Cell Proliferation; Cytoprotection; Decitabine; Diabetes Mellitus; Diabetic Nephropathies; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Male; Mice, Inbred C57BL; Podocytes; Promoter Regions, Genetic; RNA Interference; Sp1 Transcription Factor; Time Factors; Transcription Factor RelA; Transfection

2017